Table 3.

Cox univariate overall survival (OS) and progression-free survival (PFS) analysis in the ELISA (serum SDC1 concentration) and IHC cohort (SDC1 expression). HR—hazard ratio, CI—confidence interval, ECOG — Eastern Cooperative Oncology Group. Bold printed p-values were significant (<0.05).

Cox Univariate Analysis
		ELISA Cohort					IHC Cohort
Variables	Overall Survival			Progression-Free Survival			Overall Survival			Progression-Free Survival
	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Age >65	1.119	0.553–2.266	0.755	0.403	0.142–1.145	0.088	1.292	0.722–2.312	0.388	1.358	0.790–2.344	0.268
Female	0.648	0.266–1.581	0.340	0.934	0.303–2.877	0.906	1.460	0.718–2.969	0.296	1.396	0.732–2.664	0.311
Invasive stage (≥pT2)	0.659	0.279–1.558	0.342	0.760	0.234–2.474	0.649	1.049	0.506–2.175	0.897	1.292	0.630–2.649	0.484
ECOG status (≥1)	1.391	0.703–2.757	0.343	1.641	0.804–3.349	0.173	2.306	1.276–4.169	0.006	2.088	1.209–3.606	0.008
Lymph node positivity	0.990	0.369–2.655	0.983	1.838	0.414–8.158	0.423	0.542	0.285–1.030	0.061	0.598	0.322–1.108	0.102
Distant metastasis	2.459	1.147–5.273	0.021	7.832	2.627–23.349	<0.001	1.881	1.026–3.446	0.041	1.662	0.954–2.894	0.073
Serum SDC1 >180 ng/mL	1.433	1.109–1.852	0.006	1.236	0.868–1.758	0.240
Membrane SDC1 positivity							1.165	0.652–2.080	0.606	0.917	0.538–1.564	0.750
Cytoplasm SDC1 positivity							0.777	0.415–1.453	0.429	0.951	0.517–1.751	0.873
Stroma SDC1 positivity							0.685	0.377–1.245	0.214	0.837	0.485–1.446	0.524